RTS, S is the most advanced candidate vaccine against human malaria. During its
remarkable journey from conception and design in the early 1980s to the multicenter Phase …

RTS, S is the world's most advanced malaria vaccine candidate and is intended to protect
infants and young children living in malaria endemic areas of sub‐Saharan Africa against …

Malaria caused by Plasmodium falciparum remains a major public health threat, especially
among children and pregnant women in Africa. An effective malaria vaccine would be a …

Although vaccines would be the ideal tool for control, prevention, elimination, and
eradication of many infectious diseases, developing of parasites vaccines such as malaria …

Development of an effective malaria vaccine that could be deployed widely in endemic
areas has proved to be more difficult than was anticipated, when the first clinical trials of …

Abstract Background GlaxoSmithKline Biologicals and the PATH Malaria Vaccine Initiative
are working in partnership to develop a malaria vaccine to protect infants and children living …

Malaria vaccine development has rapidly advanced in the past decade. The very first phase
3 clinical trial of the RTS, S vaccine was completed with over 15,000 African infants and …

Highlights•Efficacy of RTS, S vaccine in children supports the concept of a malaria
vaccine.•RTS, S efficacy is limited and life-span is short so improvements are …

Abstract The RTS, S/AS candidate malaria vaccine has demonstrated efficacy against a
variety of endpoints in Phase IIa and Phase IIb trials over more than a decade. A multi …

Malaria continues to be a worldwide leading cause of morbidity and mortality, and the
development of an effective malaria vaccine remains a research imperative. Of the multiple …